Selective Orexin 1 Receptor Antagonists via Amide Derivatives
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with orexin receptor activity, such as schizophrenia and sleep disorders, lack effective orexin receptor antagonists that selectively target the orexin 1 receptor over the orexin 2 receptor.
Innovation Solution
Development of a class of amide derivatives that act as orexin receptor antagonists, specifically designed to selectively target the orexin 1 receptor, comprising a 6-membered heteroaryl group with specific substituents and a phenyl or heteroaryl group, offering potential therapeutic benefits for various psychiatric and neurological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for conditions associated with orexin receptor activity, then existing therapeutic options are available, but effective selective orexin 1 receptor antagonists are lacking
Solution Approach 1:
The patent applies local quality by introducing specific substituent groups at defined positions on the heteroaryl ring system. The heteroaryl group at position R3 and the phenyl or heteroaryl group at position R4 are strategically placed to create selective interaction with the orexin 1 receptor binding site, while other parts of the molecule maintain general pharmacophore characteristics. This localized functional differentiation enables selective antagonism of Ox1R over Ox2R.
Solution Approach 2:
The patent employs parameter changes by systematically varying the heteroatom composition (nitrogen, oxygen, sulfur) and substitution patterns of the heteroaryl ring system. By changing the heteroatom type and position, as well as the nature of substituents R1-R6, the patent optimizes binding affinity and selectivity for the orexin 1 receptor while maintaining antagonistic activity.
2Reliability
If amide derivatives with specific heteroaryl groups are developed to target orexin 1 receptor selectively, then selective antagonism is achieved, but compound complexity increases
Solution Approach 1:
The patent applies universality by designing a core heteroaryl amide structure that serves multiple functions: the heteroaryl ring system provides both the pharmacophore for receptor binding and the scaffold for introducing selective substituents. The amide linkage serves dual roles as both a structural connector and a hydrogen bonding participant in receptor interaction. This multi-functional design achieves selectivity without excessive molecular complexity.
Solution Approach 2:
The patent employs composite materials by combining the heteroaryl core structure with specific phenyl or heteroaryl substituents at defined positions. The composite molecular architecture integrates different aromatic systems with specific heteroatom compositions and substitution patterns, creating a unified structure that achieves selective orexin 1 receptor antagonism through synergistic interactions of its components.
Data Source
AI summary
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, (I) wherein L,X, Ra, Rb, R1, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.